AMGEN Inc
AMGEN Inc (AMGN) Historical Volatility
AMGN's 30 day historical volatility is 26.80%, in the 51st percentile of readings over the past year. This is an average percentile, meaning AMGEN Inc shares have moved roughly in line with their typical range. AMGN's 30 day implied volatility sits at 29.90%, with an IV Rank of 57.74%, leaving IV 3.10 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 17, 2026.
Read more
Tracking AMGN historical volatility helps you see how much AMGEN Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, AMGN's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor AMGN 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. AMGN's 30 day historical volatility, or AMGN HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing AMGN's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Historical Volatility
Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.
As of Nov 17, 2026
As of Nov 17, 2026
As of Nov 17, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →